SEARCH

SEARCH BY CITATION

References

  • 1
    Shapiro AK. Factors contributing to the placebo effect. Their implications for psychotherapy. Am J Psychother 1964;18, 73 88
  • 2
    Ernst E & Resch KL. Concept of true and perceived placebo effects. Br Med J 1995;311, 551 553
  • 3
    Hrobjartsson A. The uncontrollable placebo effect. Eur J Clin Pharmacol 1996;50, 345 348
  • 4
    Bodemar G & Walan A. Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet 1976;ii, 161 164
  • 5
    Blackwood WS, Pickard RG, Maudgal DP, Lawrence D, Northfield TC. Cimetidine in duodenal ulcer. Lancet 1976;ii, 174 176
  • 6
    Poynard T, Pignon JP, Eds Eds Acute Treatment of Duodenal Ulcer Analyses of 293 Randomized Clinical Trials. Paris: John Libbey Eurotext, 1989
  • 7
    Gudjonsson B & Spiro HM. Response to placebos in ulcer disease. Am J Med 1978;65, 399 402
  • 8
    Moerman DE. General medical effectiveness and human biology: placebo effects in the treatment of ulcer disease. Med Anthropol Q 1983;14, 13 16
  • 9
    Dobrilla G & Scarpignato C. Placebo and placebo effects: their impact on the evaluation of drug response in patients. Dig Dis 1994;12, 368 377
  • 10
    Laird NM & Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6, 5 30
  • 11
    Hedges LVFixed effects models. In The Handbook of Research Synthesis, eds Cooper H, Hedges LV. New York: Russell Sage Foundation, 1994 285 299
  • 12
    DerSimonian R & Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7, 177 188
  • 13
    Newman RD, Gitlin N, Lacayo EJ et al. Misoprostol in the treatment of duodenal ulcer refractory to H2-blocker therapy. Am J Med 1987;83(Suppl 1A)27 31
  • 14
    Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303, 1038 1041
  • 15
    Braverman AJ. Dose validation and study design criteria in current cimetidine studies. Clin Ther 1986;8(Suppl A)49 56
  • 16
    Cloud ML, Offen W, Matsumoto C. Healing and subsequent recurrence of duodenal ulcer in a clinical trial comparing nizatidine 300 mg and 100 mg evening doses and placebo in the treatment of active duodenal ulcer. Curr Ther Res 1989;45, 359 367
  • 17
    Eliakim R, Stalnikowicz R, Ackerman Z, Karmeli F, Rachmilewitz D. The effect of nizatidine on duodenal ulcer healing and on mucosal inflammation mediators. Isr J Med Sci 1994;30, 751 756
  • 18
    Euler AR, Baily RJ, Zinny MA et al. Arbaprostil (15 (R) -15-Methyl Prostaglandin E2) in a single nighttime dose of either 50 or 100 μg in acute duodenal ulcer. Gastroenterology 1989;97, 98 103
  • 19
    Gilinsky NH, Bright-Asare P, Cobert BL, et al. A multicenter, double-blind, randomized, placebo controlled comparison of nocturnal roxatidine in the treatment of active duodenal ulcer disease. Am J Gastroenterol 1992;87, 847 853
  • 20
    Gruber CM. Interpreting medical data. Arch Intern Med 1956;98, 767 773
  • 21
    Rickels K, Hesbacher PT, Weise CC, Gray B, Feldman HS. Pills and improvement: a study of placebo reponse in psychoneurotic outpatients. Psychopharmacologia 1970;16, 318 328
  • 22
    Samuels AS & Edison CB. A study of the psychiatric effects of placebo. J Louisiana State Med Society 1961;113, 114 117
  • 23
    Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997;112, 1854 1858
  • 24
    Marshall B. Helicobacter pylori. Am J Gastroenterol 1994;89, S116 S128